Navigating the Frontier of Hematologic Malignancy Therapies (2 of 5 Modules)
This activity provides an overview of novel approaches to T-cell immunotherapy, particularly the development of “off-the-shelf” T-cell therapies in the management of lymphomas and other hematologic malignancies.
Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Educational Objectives
Upon completion of this activity, participants should be better able to:
Identify potential T-cell immunotherapeutic strategies for the treatment of lymphomas and other hematologic malignancies
Activity Faculty
Helen E. Heslop, MD, DSc (Hon) (Chair)
Professor, Departments of Medicine and Pediatrics Director, Center for Cell and Gene Therapy Dan L. Duncan Chair Interim Director, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX